Wall Street analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to announce $8.26 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Conatus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.79 million and the lowest estimate coming in at $7.50 million. Conatus Pharmaceuticals posted sales of $9.74 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15.2%. The company is scheduled to issue its next earnings results on Wednesday, May 1st.
On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $32.85 million for the current fiscal year, with estimates ranging from $24.56 million to $40.00 million. For the next financial year, analysts anticipate that the business will report sales of $18.25 million, with estimates ranging from $1.50 million to $35.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative return on equity of 82.49% and a negative net margin of 53.62%. The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $8.63 million.
Several hedge funds and other institutional investors have recently made changes to their positions in CNAT. Two Sigma Investments LP lifted its holdings in shares of Conatus Pharmaceuticals by 761.1% during the fourth quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock valued at $433,000 after purchasing an additional 221,044 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Conatus Pharmaceuticals by 13.4% during the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after purchasing an additional 191,287 shares during the last quarter. Hikari Power Ltd purchased a new stake in shares of Conatus Pharmaceuticals during the fourth quarter valued at $289,000. Sofinnova Investments Inc. lifted its holdings in shares of Conatus Pharmaceuticals by 18.4% during the fourth quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock valued at $1,104,000 after purchasing an additional 99,282 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Conatus Pharmaceuticals by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 33,827 shares during the last quarter. 27.41% of the stock is owned by institutional investors and hedge funds.
Shares of CNAT stock opened at $0.80 on Tuesday. Conatus Pharmaceuticals has a fifty-two week low of $0.73 and a fifty-two week high of $6.74. The stock has a market cap of $36.92 million, a P/E ratio of -1.36 and a beta of 3.27.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Article: What is a Market Correction?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.